Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series |
Type de publication | Journal Article |
Year of Publication | 2021 |
Auteurs | Frechet L, Puzenat E, Charollais R, Dresco F, Carlet C, Gallais-Serezal I, Nardin C, Aubin F |
Journal | EUROPEAN JOURNAL OF DERMATOLOGY |
Volume | 31 |
Pagination | 81-85 |
Date Published | JAN |
Type of Article | Article |
ISSN | 1167-1122 |
Mots-clés | Adalimumab, infliximab, issecting cellulitis of the scalp |
Résumé | Background Dissecting cellulitis of the scalp (DCS), also known as Hoffmann disease or perifolliculitis capitis abscedens et suffodiens, is a rare disease characterized by chronic inflammation of the scalp. Treatment is difficult and often disappointing. Objectives To report our experience of TNF inhibitors in a series of patients with DCS. Materials & Methods We conducted a monocentric retrospective study of nine patients with DCS treated with TNF blocker after failure of other conventional treatments. Results After a mean duration of treatment by TNF inhibitors of 17 +/- 16 months, four patients (44% versus 0%) had a Physician's Global Assessment score of 0 or 1. We observed a 67% reduction in the number of inflammatory nodules, an 88% reduction in purulent drainage and a 45% improvement in Dermatology Life Quality Index. The mean treatment satisfaction index was 6.6 +/- 1.6 out of 10. Conclusion Our study suggests that TNF inhibitors are effective against disease activity and may improve quality of life in the management of DCS refractory to conventional treatments. |
DOI | 10.1684/ejd.2021.3969 |